studies

400A AASLD ABSTRACTS HEPATOLOGY, October, 2015
ing program were achieved as all of the patients completed
the follow-up till dead. Forty patients were identified as HCC
during the 10 years follow-up. The totally 1-, 3-, 5-, and 10-year
cumulative HCC incidence rate were 1.6% (n=6), 4.6%(n=18),
7.1%(n=27) and 10.5% (n=40) respectively. Among 40 HCC
patients, thirty-eight (95%) were identified as asymptomatic
subclinical early HCC with tumor size less than 3.0cm, and
without portal vein infiltration or metastasis. Thirteen patients
had the chance of surgical operation, and 12 (92.3%) patients
survived with no recurrence. Twenty-five patients received
radiofrequency ablation or other palliative therapy because of
liver function reserve limitation. Though totally sixteen patients
died, only 3 (18.8%) patients died of HCC(two were late stage
HCC with metastasis, one was liver failure after operation),
other 13(81.2%) patients died of concomitant liver decompensation
complications. The median survival time is 3 years after
identification of HCC. The totally 1-, 3-, and 5-year survival
rate of HCC patients were 97.5%, 91.2%, 67.7% respectively.
Conclusion: This 10 years regular integrated follow-up experience
indicates that HCC surveillance using ultrasonography
at six month intervals really performs good with early HCC
detection rate of 95%.
Disclosures:
Jidong Jia - Consulting: BMS, MSD, Roche
The following authors have nothing to disclose: Xiaoning Wu, Xiaoming Wang,
yameng sun, Yuanyuan Kong, Yu Wang, Xinyan Zhao, Qianyi Wang, Weijia
Duan, Hong You, Xiaojuan Ou
375
Integrator complex subunit 6 (INTS6) is a prognostic
marker for hepatocellular carcinoma
Minqiang Lu 1 , Ka Yin LUI 1 , Rongdang Fu 1 , Haoran Peng 1,2 , Huan
Chen 1 ; 1 Hepatic Surgery, The Third Affiliated Hospital of Sun Yatsen
University, Guangzhou, China; 2 Division of Gastroenterology
and Hepatology, The Johns Hopkins Hospital, Baltimore, MD
Purpose: Integrator complex subunit 6 (INTS6), previously
known as the gene encoding deleted in cancer cells 1 (DICE1)
was found to play a tumor suppressive role in certain types of
solid tumors just like prostate cancer and cervical cancer. However,
the clinical characteristic of INTS6 hasn’t been reported
by far. In this study, we wanted to investigate the expression of
INTS6 in hepatocellular carcinoma (HCC) and evaluated the
clinical characteristic and prognosis in HCC patients. Material
and methods: (1) Firstly, the expression level of INTS6 mRNA
were measured in a cohort of 50 HCC tissues and adjacent
normal liver tissues by using the qRT-PCR; (2) Secondly, the
expression level of INTS6 protein were detected in 20 paired
HCC and corresponding adjacent normal tissue by using western
blot; (3) At last, Immunohistochemistry was performed on
70 archived paraffin-embedded HCC samples. Results: qRT-
PCR and western blot analyses showed the INTS6 mRNA and
protein expression was significantly down-regulated in tumor
tissues compared to adjacent normal liver tissues (p